Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Genomics and Phylogenetic Studies, Breast Cancer Treatment Studies, Bacteriophages and microbial interactions, and RNA and protein synthesis mechanisms.
De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
Senkyunolide H reverses depression-induced breast cancer progression by regulating CXCR2
Xiaoyao San reverses the pro-breast cancer effect of depression by inhibiting glutamate levels in intestinal flora
Effect of Danlu capsules for the treatment of breast hyperplasia with mastalgia: a multicenter, double-blind, randomized controlled trial protocol
<i>Prevotella copri</i> exhausts intrinsic indole-3-pyruvic acid in the host to promote breast cancer progression: inactivation of AMPK via UHRF1-mediated negative regulation
Targeting lipid reprogramming in the tumor microenvironment by traditional Chinese medicines as a potential cancer treatment
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
Breast cancer prediction model based on clinical and biochemical characteristics: clinical data from patients with benign and malignant breast tumors from a single center in South China
Corrigendum to “Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway” [Canc. Lett. (2023) 216142]
Prevotella copri exhausts host’s intrinsic indol-3-pyruvid acid to promote breast cancer development: Inactivation of AMPK via UHRF1-mediated negative regulation
Bruceae Fructus Oil Inhibits Triple-Negative Breast Cancer by Restraining Autophagy: Dependence on the Gut Microbiota-Mediated Amino Acid Regulation
Neoadjuvant chemotherapy choices from population selection to regimen design: the St. Gallen International Expert Consensus Conference 2021
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
Physicians’ attitudes towards reproduction in young patients with early breast cancer in China
MCL-1 plays an oncogenic role in breast cancer by modulating chemoresistance and stemness properties by activating Wnt/β-catenin
Metabolic biomarker signature for predicting the effect of neoadjuvant chemotherapy of breast cancer
Anti-breast Cancer Enhancement of a Polysaccharide From Spore of Ganoderma lucidum With Paclitaxel: Suppression on Tumor Metabolism With Gut Microbiota Reshaping
Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin‐1‐targeting oxidant damage
Effect of Jianpi Bushen formula on aromatase-inhibitor-associated bone loss after menopause
Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin